Cutaneous lupus erythematosus

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
6 Unique sponsors
6 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody (immune) 1 substance
JAK inhibitor 1 substance
Monoclonal antibody 1 substance
Phase III: 2 Phase II/III: 1 Phase II: 4

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • AstraZeneca AB Commercial
    ANIFROLUMAB
    2023-503692-24-00 13 countries 2024 n=344
    Ended
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-504863-17-00 11 countries 2024 n=205
    Recruiting

Phase II/III

1 trial
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-505634-94-00 11 countries 2023 n=217
    Recruiting

Phase II

4 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    DEUCRAVACITINIB
    2023-504161-22-00 3 countries 2021 n=36
    Ended
  • Gilead Sciences Inc. Commercial
    GS-5718-03
    2022-501523-24-00 3 countries 2023 n=20
    Ended
  • Pfizer Inc. Commercial
    HUMANISED IGG1K MONOCLONAL ANTIBODY AGAINST INTERFERON BETA
    2023-503343-33-00 2 countries 2023 n=10
    Ended
  • Ventus Therapeutics U.S. Inc. Commercial
    VENT-03
    2024-520098-12-00 6 countries 2026 n=13
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Biogen Idec Research Limited Commercial 2 Phase II/III, Phase III 2
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase II 0
Gilead Sciences Inc. Commercial 1 Phase II 0
Pfizer Inc. Commercial 1 Phase II 0
Ventus Therapeutics U.S. Inc. Commercial 1 Phase II 1
AstraZeneca AB Commercial 1 Phase III 0
New trials by year
2021
1
2023
3
2024
2
2026
1
← All indication landscapes